ATLANTA, GA – – (Newsfile Corp. – October 30, 2020) – – Holzer & Holzer, LLC is investigating whether Intercept Pharmaceuticals, Inc. (“Intercept” or the “Company”) (NASDAQ: ICPT) complied with federal securities laws. In its most recent 10-Q filed with the SEC, the Company disclosed “the FDA has notified us that in the course of its routine safety surveillance, in May 2020 the FDA began to evaluate a newly identified safety signal regarding liver disorder for Ocaliva which the FDA classified as a potential risk.” The price of Intercept’s stock fell following the announcement. If you purchased shares of Intercept and suffered a loss on that investment, you are encouraged to contact Corey D. Holzer, Esq. at firstname.lastname@example.org or Luke R. Kennedy, Esq. at email@example.com, or by toll-free telephone at (888) 508-6832 to discuss your legal rights.